Efficacy and Biomarker Analysis of Neoadjuvant Disitamab Vedotin (RC48-ADC) Combined Immunotherapy in Patients with Muscle-Invasive Bladder Cancer: A Multi-Center Real-World Study.

Jiao Hu, Luzhe Yan, Jinhui Liu,Minfeng Chen,Peihua Liu, Dingshan Deng, Chaobin Zhang, Yunbo He,Benyi Fan,Huihuang Li,Guanghui Gong, Jiatong Xiao, Ruizhe Wang,Xiao Guan,Shiyu Tong,Yangle Li, Nannan Li, Zhiwang Tang, Teng Zhang, Hao Li, Bin Huang, Ning Gao,Wei He, Zhiyong Cai, Yifan Liu,Zefu Liu,Yu Gan,Yu Cui,Yuanqing Dai,Yi Cai, Zhenyu Nie,Zhenyu Ou,Jinbo Chen,Xiongbing Zu

iMeta（2025）

Cited 0|Views0

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined